Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186589
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2005-09-14
Brief Title:
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
90Y-Ibritumomab Tiuxetan and Autologous Hematopoietic Cell Infusion Followed by High Dose Chemotherapy and Autologous Transplantation for Relapsed or Resistant Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkins Lymphoma
Detailed Description:
This is a single center phase I dose escalation trial of a single course of IDEC-Y2B8 90Y-ibritumomab tiuxetan Zevalin with autologous peripheral blood progenitor cell infusion followed by high dose chemotherapy and AHCT for patients with relapsed or refractory B-cell NHL In step one an imaging dose of IDEC-In2B8 111In- ibritumomab tiuxetan Zevalin will be followed one week later by IDEC-Y2B both will be preceded by an infusion of 250 mgm2 rituximab Imaging will be done immediately within 1 hr at 4 - 6 hours and at 1 3 and 6 days after 90Y-ibritumomab tiuxetan
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCT00186589 | None | None | None |
| 80109 | None | None | None |
| BMT134 | None | None | None |